RTP Mobile Logo
Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Lung Cancer
Released January 2019

Featuring key slides from the most important recent lung cancer presentations and publications and a video interview with Dr Benjamin Levy. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of lung cancer.

    Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes for patients with lung cancer. However, the advent of biologic and immunotherapeutic agents has led to recent improvements in disease-free and overall survival in select populations. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing cancer clinician must be well informed of these advances.

    To bridge the gap between research and patient care, this video program features a one-on-one discussion with leading medical oncology investigator Dr Benjamin Levy. By providing information on the year’s most important presentations and publications in the context of expert perspectives, this CME activity assists medical oncologists and other allied healthcare professionals with the formulation of current, evidence-based therapeutic strategies.


    • Compare and contrast the clinical relevance of recent pivotal lung cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Appraise emerging research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy.
    • Review recent data on therapeutic advances related to the long-term care of patients with NSCLC and EGFR mutations, and integrate this information, as appropriate, into current clinical practice.
    • Communicate to appropriate patients with NSCLC the efficacy and safety of approved and investigational ALK inhibitors, considering the predictive utility of ALK mutation testing.
    • Consider age, performance status, PD-L1 tumor proportion score and other patient- or disease-related factors in the selection of induction and maintenance systemic therapy for metastatic NSCLC without an identifiable driver mutation.
    • Review published and emerging research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies used as monotherapy or in combination with chemotherapy and/or targeted therapy for newly diagnosed metastatic NSCLC.
    • Formulate management strategies for small cell lung cancer, considering the contributory roles of local and systemic therapy and the potential benefits of participation in research studies evaluating novel immunotherapeutic and targeted approaches.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of slide and video components.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Benjamin Levy, MD
    Assistant Professor
    Johns Hopkins School of Medicine
    Clinical Director
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland
    Sibley Memorial Hospital
    Washington, DC

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Lilly, Merck, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Merck and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: January 2019
    Expiration date: January 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Mutations and Genomic Alterations in Non-Small Cell Lung Cancer (NSCLC)

Immunotherapy in NSCLC

Small Cell Lung Cancer (SCLC)

Select Publications

Slide Presentation